^
+ Follow BREAST CANCER INTERNATIONAL RESEARCH GROUP Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 551569
                    [Title] => Greater chances of cure for patients with breast cancer
                    [Summary] => 

Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

[DatePublished] => 2010-02-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Freeman Cebu Lifestyle [SectionUrl] => cebu-lifestyle [URL] => ) [1] => Array ( [ArticleID] => 294479 [Title] => Beating the odds in breast cancer [Summary] => First, the bad news: The Philippines has the highest incidence of breast cancer in Southeast Asia. An estimated 14,000 new cases of breast cancer are expected to occur this year, according to a report by the Philippine Cancer Society.

Breast cancer is the leading cause of death among Filipino women, and about 6,000 of them are estimated to die from the disease this year.

The good news is that in the last few years there have been exciting developments in the treatment of breast cancer, the most common type of malignancy, next to lung cancer.
[DatePublished] => 2005-09-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 246270 [Title] => Breast cancer drug boosts survival [Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.

The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
BREAST CANCER INTERNATIONAL RESEARCH GROUP
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 551569
                    [Title] => Greater chances of cure for patients with breast cancer
                    [Summary] => 

Roche announced recently its new long-term follow up-data from two large pivotal studies evaluating adjuvant trastuzumab in HER2-positive early- stage breast cancer presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

[DatePublished] => 2010-02-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Freeman Cebu Lifestyle [SectionUrl] => cebu-lifestyle [URL] => ) [1] => Array ( [ArticleID] => 294479 [Title] => Beating the odds in breast cancer [Summary] => First, the bad news: The Philippines has the highest incidence of breast cancer in Southeast Asia. An estimated 14,000 new cases of breast cancer are expected to occur this year, according to a report by the Philippine Cancer Society.

Breast cancer is the leading cause of death among Filipino women, and about 6,000 of them are estimated to die from the disease this year.

The good news is that in the last few years there have been exciting developments in the treatment of breast cancer, the most common type of malignancy, next to lung cancer.
[DatePublished] => 2005-09-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 246270 [Title] => Breast cancer drug boosts survival [Summary] => At least 1,500 lives could be saved every year if a drug used to treat terminal breast cancer cases is given early in the disease.

The Breast Cancer International Research Group (BCIRG) said docetaxel (distributed by Aventis Pharma Inc.) significantly improved the survival rate of women with early-stage breast cancer and reduced their risk of a relapse compared with a standard treatment. This implies that docetaxel is a potential life-saver and should not only be used in terminally ill patients to buy extra time.
[DatePublished] => 2004-04-15 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with